Subject:Information on Medicalgorithmics S.A.'s Agreement to Establish a LoanLine with BioFund Capital Management LLC

CurrentReport No: 16/2024_#160;

Date:June 26, 2024_#160;

LegalBasis: Article 17, Section 1 of the MAR Regulation - ConfidentialInformation

TheManagement Board of Medicalgorithmics S.A., based in Warsaw (_quot;Company_quot;;_quot;Issuer_quot;), announces the signing of an agreement on June 25, 2024, toestablish a loan line (_quot;Agreement_quot;) with the Company's shareholder,BioFund Capital Management LLC (_quot;BioFund_quot;). The Supervisory Board,acting under the Company's Articles of Association, adopted a resolutionon June 25, 2024, approving the Agreement.

TheAgreement provides for a loan line of up to $3 million USD, available tothe Company for a period of four years. The Company can utilize thisfinancing in tranches of up to $1 million USD for specific projectsindicated in the tranche activation requests, such as technologydevelopment, technology acquisitions, or mergers and acquisitions (M_amp;A).The loan will bear interest at a rate corresponding to the 90-dayaverage SOFR plus a 2.2% margin, and repayment will be made - unlessotherwise agreed - in 24 monthly installments, with the first repaymentdue no earlier than October 2025. Each tranche activation will be basedon a request from the Company specifying the purpose of the tranche. Asof the agreement date, the Company does not anticipate requesting anytranches from the loan line.

TheAgreement between BioFund Capital Management LLC and the Company is theexecution and formalization of BioFund's declaration related to itsinvestment in the Company in 2022, under which it acquired a 49.99%stake in the Company. BioFund has committed to further supporting theCompany's development, including providing financing of up to $3 millionUSD.